The Current Ratio as of November 2024 (TTM) for Affimed N.V. (AFMD) is 1.93

According to Affimed N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 1.93. This represents a change of -29.48% compared to the average of 2.74 of the last 4 quarters.

Affimed N.V. (AFMD) Historical Current Ratio (quarterly & annually)

How has AFMD Current Ratio performed in the past?

The mean historical Current Ratio of Affimed N.V. over the last ten years is 4.88. The current 1.93 Current Ratio has changed 3.85% with respect to the historical average. Over the past ten years (40 quarters), AFMD's Current Ratio was at its highest in in the June 2015 quarter at 13.41. The Current Ratio was at its lowest in in the September 2024 quarter at 1.93.

Affimed N.V. (AFMD) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Affimed N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Affimed N.V. (AFMD) Average Current Ratio

How has AFMD Current Ratio performed in the past?

The current Current Ratio of Affimed N.V. (AFMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Affimed N.V. (AFMD) Current Ratio vs. Peers

How is AFMD’s Current Ratio compared to its peers?

Affimed N.V.’s Current Ratio is less than TCR2 Therapeutics Inc. (2.77), less than Pieris Pharmaceuticals, Inc. (4.82), less than ADC Therapeutics SA (4.92), greater than Agenus Inc. (0.19), less than X4 Pharmaceuticals, Inc. (4.89), less than Terns Pharmaceuticals, Inc. (32.99), less than Day One Biopharmaceuticals, Inc. (14.62), less than PDS Biotechnology Corporation (2.84), less than Inozyme Pharma, Inc. (7.68), less than Leap Therapeutics, Inc. (3.97), less than Adaptimmune Therapeutics plc (3.85), greater than Corvus Pharmaceuticals, Inc. (0.92), greater than Aptose Biosciences Inc. (1.05), greater than eFFECTOR Therapeutics, Inc. (1.03), less than Elevation Oncology, Inc. (17.77), less than Mereo BioPharma Group plc (6.10), greater than Hepion Pharmaceuticals, Inc. (1.30),

Build a custom stock screener for Affimed N.V. (AFMD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Affimed N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Affimed N.V. (AFMD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Affimed N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.